Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's research tests from Lifescreen:

This article was originally published in Clinica

Executive Summary

Lifescreen (UK) has launched two new products for use in Alzheimer's disease research. The first is an ELISA that can detect as little as 3pg of b-amyloid peptide. The assay comes in a 96-well format and uses a fluorescent substrate to achieve high sensitivity, the company says. The second product is the Synthaloid AD Drug Discovery System for screening products that modify b-amyloid deposition. It uses a b-amyloid polymer matrix to mimic the behaviour of b-amyloid in the brain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel